JPWO2015098991A1 - Ｎ−アルキルアミド誘導体及びその医薬用途 - Google Patents
Ｎ−アルキルアミド誘導体及びその医薬用途 Download PDFInfo
- Publication number
- JPWO2015098991A1 JPWO2015098991A1 JP2014561630A JP2014561630A JPWO2015098991A1 JP WO2015098991 A1 JPWO2015098991 A1 JP WO2015098991A1 JP 2014561630 A JP2014561630 A JP 2014561630A JP 2014561630 A JP2014561630 A JP 2014561630A JP WO2015098991 A1 JPWO2015098991 A1 JP WO2015098991A1
- Authority
- JP
- Japan
- Prior art keywords
- mmol
- compound
- added
- pyridin
- reference example
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *[C@](c(cc1Cl)cnc1Nc1cnc(*)cc1)NC([Al])=O Chemical compound *[C@](c(cc1Cl)cnc1Nc1cnc(*)cc1)NC([Al])=O 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013269448 | 2013-12-26 | ||
| JP2013269448 | 2013-12-26 | ||
| PCT/JP2014/084204 WO2015098991A1 (fr) | 2013-12-26 | 2014-12-25 | Dérivé de n-alkylamide et son utilisation médicinale |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2015098991A1 true JPWO2015098991A1 (ja) | 2017-03-23 |
Family
ID=53478838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014561630A Pending JPWO2015098991A1 (ja) | 2013-12-26 | 2014-12-25 | Ｎ−アルキルアミド誘導体及びその医薬用途 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2015098991A1 (fr) |
| WO (1) | WO2015098991A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019126731A1 (fr) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Dérivés d'aminopyridine utilisés en tant qu'inhibiteurs de la phosphatidylinositol phosphate kinase |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| GB202018412D0 (en) * | 2020-11-23 | 2021-01-06 | Exscientia Ltd | Malt-1 modulators ii |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0620066A2 (pt) * | 2005-12-20 | 2011-11-01 | Novartis Ag | derivados de ácido nicotìnico como moduladores do receptor de glutamato metabotrópico, processo para preparação dos mesmos, composição farmacêutica e uso dos referidos derivados |
| DE102006012251A1 (de) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln |
| GB0606774D0 (en) * | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
-
2014
- 2014-12-25 WO PCT/JP2014/084204 patent/WO2015098991A1/fr active Application Filing
- 2014-12-25 JP JP2014561630A patent/JPWO2015098991A1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015098991A1 (fr) | 2015-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6917989B2 (ja) | 神経学的疾患を処置するためのムスカリン受容体４（ｍ４）アンタゴニストとしての、ｎ−［２−（１−ベンジルピペリジン−４−イル）エチル］−４−（ピラジン−２−イル）−ピペラジン−１−カルボキサミド誘導体および関連化合物 | |
| JP5909312B2 (ja) | カルシウム放出依存性カルシウムチャネルのピラゾール誘導体モジュレータおよび非小細胞肺癌の治療方法 | |
| CN107428690B (zh) | 可用于治疗癌症的突变idh1抑制剂 | |
| JP5715713B2 (ja) | 可溶性グアニル酸シクラーゼ活性化因子 | |
| US10105359B2 (en) | Tetrahydroisoquinoline derivatives | |
| US9624215B2 (en) | Amine derivative or salt thereof | |
| KR102117453B1 (ko) | 5-아릴알키닐기에 의해 치환된 벤즈아미드계 화합물 및 이의 제조방법, 약물 조성물과 용도 | |
| JP2016169231A (ja) | Ｍｇｌｕｒ５の負のアロステリック調節剤としての６−アルキル−ｎ−（ピリジン−２−イル）−４−アリールオキシピコリンアミド類似体ならびにそれを作製および使用する方法 | |
| TWI691475B (zh) | Ｕｒａｔ１抑制劑 | |
| JP2012525390A (ja) | 置換イミダゾ［１，２−ａ］ピリジン誘導体、医薬組成物、及びβ−セクレターゼ阻害剤としての使用方法 | |
| JP5587246B2 (ja) | レニン阻害剤としての３，４−置換ピペリジン誘導体 | |
| CA2651857A1 (fr) | Derives d'aryl-4-ethynyl-isoxazole | |
| JP6629884B2 (ja) | 哺乳動物のチロシンキナーゼｒｏｒ１活性の阻害剤として有用な２−フェニル−３ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体 | |
| JPWO2016031987A1 (ja) | オートタキシン阻害活性を有するピリミジノン誘導体 | |
| EP2477492A1 (fr) | Analogues d'hétéroarylamine carboxamide substitué utilisés comme modulateurs allostériques négatifs de mglur5, leurs procédés de préparation et d'utilisation | |
| KR20160115996A (ko) | 피라졸론 화합물 및 이의 용도 | |
| CN107635970A (zh) | 苯并咪唑酮和苯并噻唑酮化合物以及它们作为ampa受体调节剂的用途 | |
| JP2011520924A (ja) | レニン阻害剤としての３，４−置換ピペリジン誘導体 | |
| JPWO2010007944A1 (ja) | 含窒素二環性複素環化合物 | |
| JP2013526610A (ja) | Ｍｇｌｕｒ５の正のアロステリック調節剤としての置換６−メチルニコチンアミド | |
| JPWO2015098991A1 (ja) | Ｎ−アルキルアミド誘導体及びその医薬用途 | |
| WO2023134751A1 (fr) | Inhibiteur double cible de tubuline-src et son utilisation | |
| JPWO2013081094A1 (ja) | イミダゾ［１，２−ａ］ピリジン誘導体及びその医薬用途 | |
| JP2017534588A (ja) | グループｉｉの代謝型グルタミン酸受容体のアロステリックモジュレーターとしての置換ピラゾロキナゾリノンおよびピロロキナゾリノン | |
| CN110105286B (zh) | 一种含有脲素骨架的取代杂环类化合物及其制备方法和用途 |